Supplemental Figure 2 | Supplemental flow plots

a Proportion of CD45+CD4+Foxp3− T cells, CD45+CD4+Foxp3+ Tregs, CD45+CD3+CD8+ T cells, CD45+F4/80−Ly-6G−CD11c+ cells, or CD45+CD11b+Gr-1− cells from LY2 or MOC2 tumors harvested 4 or 3 days post-RT, respectively, compared to 0 Gy controls (n=3 mice/group).

b Proportion of CD45+CD3+CD4+Foxp3−CD44hiCD62Llo T cells or CD45+CD3+CD8+CD44hiCD62Llo T cells from LY2 or MOC2 tumors harvested 4 or 3 days post-RT, respectively, compared to 0 Gy controls (n=3 mice/group).

c Proportion of CD45+CD3+CD4+Foxp3− T cells or CD45+CD3+CD8+ T cells in MOC2 tumors harvested 9 days post-RT with RT or RT + anti-CD25 treatment (n=5 mice/group).

d Proportion of CD45+CD3+CD4+Foxp3− T cells or CD45+CD3+CD8+ T cells in MOC2 tumor draining lymph nodes harvested 9 days post-RT with RT or RT + anti-CD25 treatment (n=5 mice/group).

e Proportion of CD45+CD3+CD4+Foxp3− T cells expressing IFNγ or TNFα in MOC2 tumors harvested 9 days post-RT with RT or RT + anti-CD25 treatment (n=5 mice/group).

f Proportion of CD45+CD3+CD8+ T cells expressing IFNγ or TNFα in MOC2 tumors harvested 9 days post-RT with RT or RT + anti-CD25 treatment (n=5 mice/group).

Supplemental material BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

of CD45^+CD3^+CD4^+Foxp3^- T cells expressing IFN\(\gamma\) or TNF\(\alpha\) in MOC2 tumor draining lymph nodes harvested 9 days post-RT with RT or RT + anti-CD25 treatment (n=5 mice/group). **h** Proportion of CD45^+CD3^+CD8^+ T cells expressing IFN\(\gamma\) or TNF\(\alpha\) in MOC2 tumor draining lymph nodes harvested 9 days post-RT with RT or RT + anti-CD25 treatment (n=5 mice/group).